Sign inJoin waitlistJoin the waitlist

Vaia Florou

Associate Professor · Univ of Utah Sch of Med

Credentials: · · · · · · ·

History

Univ of Utah Sch of Med
Present

Hematology and Medical Oncology
2015–2018
Internal Medicine
2012–2015
Doctor of Medicine
2006–2010

Research

Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial
The Lancet Oncology · 2019 · 331 citations
Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution
Journal for ImmunoTherapy of Cancer · 2019 · First of 10 authors · Corresponding · 158 citations
Considerations for treatment duration in responders to immune checkpoint inhibitors
Review · Journal for ImmunoTherapy of Cancer · 2021 · 112 citations

Ignacio Garrido-Laguna
15 papers
Breelyn Wilky
10 papers
Christopher Nevala-Plagemann
9 papers · 7 as a resident
Jonathan Trent
9 papers
Abdul Naqash
5 papers · 1 as a fellow
WP
Wungki Park
5 papers
Heloisa Soares
4 papers
Sonam Puri
4 papers
David Shibata
3 papers
Emil Lou
3 papers
Peter Hosein
3 papers
Zachary Rubnitz
3 papers · 3 as a resident

Grants

Exploration of Novel Mutation Biomarkers to Repurpose EGFRi for Mutant KRAS Colorectal Cancer
National Cancer Institute · R21
Contact PI · $392.1K · Utah State Higher Education System--University of Utah
2021–2025

Clinical trials

Cetuximab in Third Line for Mutant APC, TP53 and RAS Patients With Refractory Metastatic Colorectal Cancer
Principal investigator · Terminated · Phase 2
University of Utah
2021–2024
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
Site PI · Recruiting · Phase 1, Phase 2
Tango Therapeutics, Inc.
2025–2027
Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes
Site PI · Recruiting · Phase 1
National Cancer Institute (NCI)
2023–2028
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
Site PI · Recruiting · Phase 1, Phase 2
Tango Therapeutics, Inc.
2023–2028